Aspirin resistance and atherothrombotic disease.

[1]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[2]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[3]  P. Gazzaniga,et al.  Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. , 2004, Journal of the American College of Cardiology.

[4]  Deepak L. Bhatt,et al.  Aspirin dose and six-month outcome after an acute coronary syndrome. , 2004, Journal of the American College of Cardiology.

[5]  C. Lau,et al.  Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. , 2004, Journal of the American College of Cardiology.

[6]  Z. Vered,et al.  Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? , 2004, American heart journal.

[7]  C. Patrono,et al.  Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[8]  P. Block,et al.  Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. , 2003, The American journal of cardiology.

[9]  P. Marshall,et al.  A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. , 2003, British journal of clinical pharmacology.

[10]  J. Michael Gaziano,et al.  Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs , 2003, Circulation.

[11]  K. Schrör,et al.  Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery , 2003, Circulation.

[12]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[13]  S. Frøland,et al.  Interleukin-7–Mediated Inflammation in Unstable Angina: Possible Role of Chemokines and Platelets , 2003, Circulation.

[14]  Deepak L. Bhatt,et al.  Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. , 2003, Archives of internal medicine.

[15]  J. Freedman.  CD40-CD40L and platelet function: beyond hemostasis. , 2003, Circulation research.

[16]  P. Gurbel,et al.  Durability of platelet inhibition by clopidogrel. , 2003, The American journal of cardiology.

[17]  M. Gawaz,et al.  Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.

[18]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[19]  D. Atar,et al.  Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. , 2003, European journal of pharmacology.

[20]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[21]  H. Arnesen,et al.  Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. , 2002, Thrombosis research.

[22]  P. Järemo,et al.  Individual variations of platelet inhibition after loading doses of clopidogrel , 2002, Journal of internal medicine.

[23]  L. Christiaens,et al.  Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. , 2002, Thrombosis research.

[24]  A. Hingorani,et al.  Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin , 2002, Circulation.

[25]  C. Patrono,et al.  Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[27]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[28]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[29]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[30]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[31]  C. Beythien,et al.  Platelet hemostasis capacity in smokers. In vitro function analyses with 3.2% citrated whole blood. , 2001, Thrombosis research.

[32]  Kenneth G. Mann,et al.  PlA2 Polymorphism of &bgr;3 Integrins Is Associated With Enhanced Thrombin Generation and Impaired Antithrombotic Action of Aspirin at the Site of Microvascular Injury , 2001, Circulation.

[33]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[34]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[35]  E. Topol,et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.

[36]  S. Devaraj,et al.  Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. , 2001, Journal of the American College of Cardiology.

[37]  H. Arnesen,et al.  Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. , 2000, Thrombosis research.

[38]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[39]  M. Furman,et al.  Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. , 2000, Circulation.

[40]  J. Kambayashi,et al.  Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. , 2000, Stroke.

[41]  B. Jilma,et al.  Monitoring of Aspirin (ASA) Pharmacodynamics with the Platelet Function Analyzer PFA-100® , 2000, Thrombosis and Haemostasis.

[42]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[43]  R. Califf,et al.  Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. , 1999, The American journal of cardiology.

[44]  V. Fuster,et al.  Platelet-Active Drugs , 1998 .

[45]  L. Feigen,et al.  Assessment of platelet function assays. , 1998, American heart journal.

[46]  C. Patrono,et al.  Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease , 1998, Thrombosis and Haemostasis.

[47]  A. Marcus,et al.  Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. , 1998, Circulation.

[48]  U. Losert,et al.  Variable Platelet Response to Low-dose ASA and the Risk of Limb Deterioration in Patients Submitted to Peripheral Arterial Angioplasty , 1997, Thrombosis and Haemostasis.

[49]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[50]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[51]  J. Hung,et al.  Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. , 1995, Circulation.

[52]  S. Brister,et al.  Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. , 1995, The Canadian journal of cardiology.

[53]  L. Brace,et al.  Development of Aspirin Resistance in Persons With Previous Ischemic Stroke , 1994, Stroke.

[54]  B. Bull,et al.  Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. , 1994, Archives of pathology & laboratory medicine.

[55]  C. Patrono.  Aspirin as an antiplatelet drug. , 1994, The New England journal of medicine.

[56]  P. T. Larsson,et al.  Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. , 1994, Circulation.

[57]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[58]  K. Grotemeyer,et al.  Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. , 1993, Thrombosis research.

[59]  K. Grotemeyer.  Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. , 1991, Thrombosis research.

[60]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[61]  B. Weksler,et al.  Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. , 1983, The New England journal of medicine.

[62]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[63]  C. Pepine,et al.  Platelet aggregation studies in coronary artery disease. Past 4. Effect of aspirin. , 1978, Atherosclerosis.

[64]  G. Tofler,et al.  Effect of Short-Term Aspirin Use on C-Reactive Protein , 2004, Journal of Thrombosis and Thrombolysis.

[65]  H. Topka,et al.  Aspirin non-responder status in patients with recurrent cerebral ischemic attacks , 2003, Journal of Neurology.

[66]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[67]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[68]  Craven Ll.  Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. , 1953 .